Perceptive Advisors is launching a NewCo around soticlestat, Ovid Therapeutics and Takeda's failed epilepsy drug, with up to $294.5 million in milestones owed to Ovid.
About 26 months after failing two Phase 3 trials, an epilepsy treatment candidate is getting plucked off biopharma’s shelves and will be given a new …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
After coming up short in trials with two orexin type 2 receptor (OX2R) selective agonists, Takeda has scored with oveporexton,
With a formidable new competitor set to enter the orexin development race, Takeda is out with new data it hopes reinforces…
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with…
Takeda's Orzeyful wins FDA approval as the first full-symptom narcolepsy type 1 drug, kicking off an orexin agonist race with…
Could a new class of drugs being used to treat rare neurological disorders allow people to function without sleep?
Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an…
